

Award Number: **W81XWH- 12-1-0150**

TITLE:

“Activation of Antitumorigenic Stat3beta in Breast Cancer by Splicing Redirection”

PRINCIPAL INVESTIGATORS:

ELISA de STANCHINA, PhD

CONTRACTING ORGANIZATION:

Memorial Sloan Kettering Cancer Center

1275 York Avenue New York

REPORT DATE:

July 2013

TYPE OF REPORT:

ANNUAL REPORT

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

X Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation

REPORT DOCUMENTATION PAGE			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE July 2013		2. REPORT TYPE Annual		3. DATES COVERED 1 Jul 2012 - 30 Jun 2013	
4. TITLE AND SUBTITLE Activation of Antitumorigenic Stat3beta in Breast Cancer by Splicing Redirection			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH- 12-1-0150		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) ELISA de STANCHINA, PhD Email: destance@mskcc.org			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Memorial Sloan Kettering Cancer Center NEW YORK, NY 10065			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Signal transducer and activator of transcription 3 (STAT3) is a transcription factor constitutively active in a large number of tumors, where it works as a central player in the activation of multiple oncogenic pathways and contributes to the proliferative state, the migratory and invasive potential and to the maintenance of the mesenchymal phenotype. STAT3 therefore constitutes a potential prime target for directed cancer therapies. A naturally occurring alternative splicing variant, STAT3 β , uses an alternative acceptor site within exon 23 and leads to the production of a truncated isoform, which lacks the C-terminal trans-activation domain (TAD). Depending on context, STAT3 β can act as a dominant negative regulator of transcription and promote apoptosis. We have used modified antisense oligonucleotides to specifically induce a shift of expression from the abundant, active STAT3 α to the truncated STAT3 β isoform. Induction of the endogenous STAT3 β leads to decreased cell viability in cell lines with persistent STAT3 tyrosine phosphorylation, compared to full STAT3 knock-down obtained by Forced Splicing-Dependent Nonsense-Mediated Decay (FSD-NMD). Furthermore, comparison of the molecular effects of splicing redirection to STAT3 knock-down reveals a unique STAT3 β transcriptional signature, with the downregulation of specific target genes (including LEDGF, PCAF, Cyclin C, PEX1 and STAT1b) distinct from canonical STAT3 genes typically associated to total STAT3 knock-down. Here we propose to screen a next generation panel of antisense compounds, to reprogram STAT3 splicing in cancer cells in vitro and in vivo, in different genetic and orthotopic mouse models, to establish a working model system to test the approach.					
15. SUBJECT TERMS- stat3, alternative splicing, antisense, oligonucleotide, cancer, therapy					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)
			UU	18	

Table of Contents


	<u>Page</u>
Introduction.....	3
Body.....	7
Key Research Accomplishments.....	13
Reportable Outcomes.....	13
Conclusion.....	14
References.....	16
Appendices.....	n/a
Supporting data.....	n/a

INTRODUCTION

Signal transducer and activator of transcription (STAT) proteins are a family of transcription factors implicated in growth factors and cytokines signalling [1]. In the canonical model of STATs signalling, single monomers are normally sequestered in the cytoplasm in an inactive form. Their activation is initiated by tyrosine phosphorylation, usually mediated by the binding of cytokines or growth factors to their membrane receptors and/or by intracellular oncogenic tyrosine kinases, such as JAKs and Src. Upon cytoplasmic tyrosine phosphorylation, two STAT monomers dimerize, translocate to the nucleus and bind to specific promoter sequences, thereby regulating gene expression[1]. Under physiological conditions, every phospho-STAT protein has a limited activation period that typically lasts from a few minutes to several hours, while persistent activation of STAT proteins, in particular STAT3 and STAT5, is observed in a wide variety of cancers, including breast cancer[2].


STAT3 is implicated in a vast range of physiological processes including cellular proliferation, differentiation, inflammation and immune response[3-6], but can also act as an oncogene to induce cellular transformation and tumorigenesis[7]. Indeed, persistently tyrosine phosphorylated STAT3 has been reported in nearly 70% of haematological and solid tumors[8]. Because of its wide range of functions, STAT3 is involved in many aspects of carcinogenesis such as proliferation, survival, angiogenesis and metastasis[9,10] and can also contribute to tumor escape from immune surveillance[11,12] and to the establishment of tumor drug resistance[13,14]. Consistently, persistent activation of Stat3, has been reported in human breast carcinoma cell lines but not in mammary epithelial cell lines derived from non-malignant tissues[15,16].

STAT3's pivotal position at the convergence of many oncogenic tyrosin-kinase signalling pathways, makes it a particularly suitable molecular target for cancer therapy,



especially considering that tumor cells tend to become dependent on persistent STAT3 signalling and are more sensitive to its inhibition than normal cells[8,17]. Indeed, direct inhibition of STAT3 activities by multiple means, such as overexpression of dominant negative isoforms[18], antisense oligonucleotides[19], RNAi[20,21] or small drug inhibitors[22] results in growth inhibition and induces apoptosis in breast cancer and other model systems[23]. The direct implication of Stat3 as a promoter of breast tumor growth and progression is further supported by the observation that breast tumor sample show increased Stat3 activity compared to matched non neoplastic tissues, but decreased in samples from patients with a complete pathological response to doxorubicin/docetaxel treatment compared to partial responders[24].

Inhibition of STAT3 activity therefore represents a promising approach in the treatment of breast cancer.




A naturally occurring alternative splicing variant, STAT3-beta, uses an alternative acceptor site within exon 23 (Figure 2) and leads to the production of a truncated isoform lacking the C-terminal transactivation domain (TAD). As a consequence, STAT3-beta can still heterodimerize with the full-

length STAT3 (STAT3-alpha) and bind to DNA, but it cannot transactivate gene expression, thus effectively blocking STAT3 signalling. Indeed, STAT3-beta can act as a dominant negative regulator of transcription, and its overexpression leads to a significant inhibition of tumor growth and increased apoptosis, both *in vitro* and *in vivo*.

Redirection of STAT3 alternative splicing therefore presents an attractive way to eliminate the tumorigenic STAT3 alpha variant while simultaneously inducing the generation of the STAT3beta variant, which possesses marked anti-tumoral properties.

In the previous CDMRP-BCRP-funded study (BC074961, Modulation of Stat3 Alternative Splicing in Breast Cancer), we induced the STAT3beta isoform using an antisense approach, where modified oligonucleotides were very specifically targeted to splicing regulatory elements to either inhibit or promote the usage of splicing sites[25]. Use of



antisense compounds is a well-established approach for gene expression regulation[26], and normally relies on the destabilization of the target mRNAs, either by triggering RNase H degradation or by taking advantage of the RNAi mechanism. Redirection of splicing differs from the standard antisense-based approach in that the objective is not degradation of the target RNA. On the contrary, triggering of RNase H must be

avoided in order to preserve the integrity of the re-directed mRNA, and therefore different chemical characteristics must be present in the antisense compounds.


Morpholino phosphorodiamidate oligonucleotides (morpholinos) are DNA oligonucleotide analogues in which the phosphodiester bond is replaced by phosphorodiamidate linkage and the ribose is replaced by a morpholino moiety. Because of its noncharged backbone, morpholinos form very stable duplexes with single-stranded RNA targets and are highly resistant to nucleases and proteases. We had previously developed chimeric compounds that are coupling to the antisense moiety of a peptide (RS-rich) that mimics the action of the “RS domain”, the ‘activation domain’ of splicing factors[27]. In addition, Arginine-rich peptides share structural similarities to translocating peptides (like TAT) that are able to mediate free-uptake of bound cargo into cells. In addition, we have also used a formulation of the compounds (vivo-morpholino) where a cationic dendrimer is coupled to the oligonucleotide instead of the peptide. This variant was originally developed by Gene-tool for *in vivo* treatments.

We thus used splicing redirection compounds to induce a switch from the alpha to the STAT3beta isoform (Figure 3).

To be able to compare the effect of the beta switch to those of a STAT3 knock-down, we adapted the splicing redirection approach to cause a total knock-down by inducing an early splicing shift of a constitutive exon, which leads to a frameshift, a Premature Termination

Codon (PTC) and eventually to degradation of the mRNA by nonsense-mediated decay (NMD). The resulting fsd-NMD (forced splice-dependent NMD) was used to completely knock-down Stat3 as a control (Figure 4 a,b). We then started to assess the biological effect of the switch in breast cancer cell lines that have different extent of Stat3 dependence. The activity was measured using a number of cell-based biological assays.

The alpha-to-beta switch induces cell death in triple-negative Stat3-dependent cell lines like MDA-MB-435s or MDA-MB-468, but not in cell lines such as MDA-453, that do not show persistent activation of Stat3 (figure 4c,d). In side-by-side experiments, however, full knock-down of Stat3 was not as effective as the splicing switch in promoting cell death, suggesting that Stat3beta may induce cell death



by a mechanism different than a straight dominant negative effect.

Indeed, we found that the alpha-to-beta switch activates a specific transcription program that includes downregulation of survival factors, including LEDGF, PCAF, Cyclin C and Stat1beta. Next, we tested whether the splicing redirection compounds also possess anti-tumor activity *in vivo*. The beta-switching compound ST2 and the knock-down compound ST6 were injected intratumorally in athymic mice carrying 435s-derived xenograft tumors [25]. The switch to beta was associated to a full regression of the tumors providing the first evidence that modulation of a single splicing event can have anti-tumoral properties. On the other hand, knock-down of total STAT3 didn't have a significant effect on tumor growth even if the treatment was very effective at the molecular level [25].

BODY

Role of Stat3beta downstream effectors [Cartegni Lab]

Our previous experiments showed that reduction of STAT3a and concomitant induction of STAT3b by alternative splicing modulation can decrease cancer cell viability more efficiently than the knockdown of both STAT3 isoforms. Therefore we set out to determine which STAT3 target genes may be involved in this process.

We thus performed a screen using cDNAs from MDA-MB-435s cells treated for 4 days with ST2 (STAT3b induction), ST6 (STAT3 K.O.) or INV (control) compounds. Expression levels were analyzed by real-time PCR, using the microarray platform U133A 2.0 (Affymetrix) [25]. Whereas knocking-down both STAT3 isoforms by FSD-NMD using the ST6 compound resulted in a somewhat modest but consistent downregulation of most canonical targets analyzed (and a robust downregulation of STAT3 itself, as expected), STAT3b induction by ST2 appears to have activated a STAT3b-specific transcriptional signature [25], indicative of the existence of different classes of target genes in terms of how they respond to STAT3a/STAT3b regulation.

Out of the panel of genes with statistically significant variation of expression levels in the microarray assay, in addition to the previously described STAT3-target interleukin 8 (IL8), five other genes were confirmed to be down-regulated both at the RNA and protein level by the switch to STAT3 β , but not by the knockdown: 1.) **Lens Epithelium-Derived Growth Factor** (LEDGF/PSIP1, a chromatin binding protein and transcriptional co-activator; a pro-survival and growth factor)[28]; 2.) **peroxisomal biogenesis factor 1** (PEX1, part of the AAA ATPase

subfamily, required for peroxisomal import)[29]; 3.) **CyclinC** (CCNC, controls transcription by associating with Cdk8 and modulating RNA pol II activity and regulates G0/G1 transition) [30]; 4.) **p300/CBP-associated factor** (PCAF, histone acetyltransferase and transcriptional co-activator, promotes growth, invasion and drug resistance)[31]; and 5.) **STAT1** (proliferative antagonist isoform of tumor suppressor STAT1)[32]. In the case of STAT1, the effect is indirect or post-transcriptional, as only the alternative splicing variant STAT1b, but not the full-length variant STAT1a is affected). Notably, the microarray analysis confirmed that none of the canonical STAT3 targets, except for IL8, were strongly down-regulated by the STAT3 β induction. LEDGF, PEX1, Cyclin C and STAT1b were also specifically down-regulated by the switch from STAT3 α to STAT3 β in MDA-MB-468 cells.

Knockdown and rescue of STAT3 β targets [Cartegni Lab]. The set of target genes specifically down-regulated when STAT3 splicing is redirected from STAT3 α to STAT3 β had not previously been associated with STAT3 β activity. In order to get a better understanding




Figure 5. Knock-down and overexpression of STAT3 β target genes. (A-E) (Left) MDA-MB-435s were treated for 72 hours with siRNA against GFP or: LEDGF (A), PEX1 (B), PCAF (C), IL8 (D) or CyclinC (E). Effective knock-down was verified by WB using specific antibodies (A-C, with α -Tubulin as control) or by qPCR analysis (D-E), displayed as $-dC(t)$ values after normalization to HPRT. (Right) Cell death quantification determined by trypan blue exclusion for MDA-MB-435s treated as described. Data are displayed as fold change of treated samples (orange) relative to control treatment (green) and represent average of three independent experiments (each in triplicates). P-values were calculated by the stratified chi-square test, bars represent standard error of the rate (SE). (F) (Left) Lysates from MDA-MB-435s transiently over-expressing LEDGF or transfected with empty vector (EV) were immunoblotted using antibody to LEDGF. (Right) The transfected cells were concurrently treated with 16 μ M of INV or ST2 morpholinos for 4 days, and cell death was quantified as above. (G-J) (Left) Stable MDA-MB-435s clones over-expressing STAT1 β (G), PCAF (H), IL8 (I), CyclinC (J) or selected for the empty vector (EV) were treated with 16 μ M of INV or ST2 morpholinos for 4 days. Over-expression levels were determined by WB using specific antibodies (G-H, with α -tubulin used as loading control) or by qPCR analysis (I-J), displayed as $-dC(t)$ values after normalization to HPRT. (Right) Cell death quantified as above.

of their contribution to the biological effects observed, we took two different approaches. First, we tested whether their individual down-regulation was able to recapitulate the decrease in cell viability observed with the ST2 treatment. MDA-MB-435s cells were treated with siRNA against five target genes (no siRNAs are available to specifically target STAT1b but not STAT1a). Effective knock-down was verified by qPCR and WB, where suitable antibodies were available (Figure 5 A-E) and cell viability was measured. Individual down-regulation of PEX1, IL8 or CyclinC did not lead to an increase in cell death (Figure 5B, D, E). On the other hand, knock-down of LEDGF (Figure 5A) and PCAF (Figure 5C), was associated to a significant decrease in cell viability.

Next we asked whether forced re-expression of the STAT3 β target genes could protect from the increase in cell death induced by the α -to- β switch. We thus generated MDA-MB-435s-derived cell lines stably expressing four of the STAT3 β target genes (STAT1b, PCAF, IL8, CyclinC). Initially we were unable to generate a stable LEDGF-expressing line, therefore the equivalent experiment (shown) was performed under transient expression conditions. However, additional stable clones are under characterization and once obtained will be also used for successive phases of the proposed experiments.

Cells were concurrently treated in vitro with either ST2 or INV compounds, and cell viability was measured after 4 days. Forced expression of STAT1b did not protect from cell death induced by the splicing switch (Fig. 5G), compared to cells selected for integration of the empty vector. Expression of IL8 (Fig. 5I) showed a reduced but still significant increase in cell death.

Most importantly, **LEDGF, PCAF and Cyclin C** protected cells from the α -to- β shift (Fig. 5F, 5H-J) as treating the overexpressing cells with ST2 had no effect on their viability, unlike what observed with control cells. Taken together these data suggest that the effect of the STAT3 β isoform on cell viability is likely mediated by the combined down-regulation of a specific set of target genes rather than exerted through a single major effector, in agreement with STAT3 pleiotropic functions in the pathogenesis of cancer.

In vivo treatment of stat3-dependent tumors [Cartegni lab, de Stanchina lab]

In preliminary experiments, we have tested how STAT3 alternative splicing modulation could affect tumor growth in vivo, using the ST2, ST6 and INV morpholino compounds described earlier, delivered by intratumoral injection. Athymic mice subcutaneously implanted with MDA-MB-435s cells were IT injected twice a week for a total of 3 weeks while monitoring for tumor growth. 13 days after the first injections tumors treated with the switching ST2

morpholino showed regression (Figure 5A-B) while tumors treated with the knock-down ST6 compound grew as well as PBS and INV-treated tumors [25].

RT-PCR for either STAT3 exon 23 (Figure 5C) or STAT3 exon 6 (Figure 5D) confirmed efficacy of both ST2 and ST6 treatments in inducing either STAT3 splicing switch or total STAT3 FSD-NMD knockdown. Tumor sections were analyzed by immunohistochemistry (IHC) with three STAT3 antibodies. Staining for total-STAT3 and P-Y705 (present in both STAT3 α and STAT3 β) was strongly decreased in ST6-treated tumors (Figure 5F, 5H), confirming that the ST6 compound was effective at substantially knocking down STAT3. On the contrary, the level of both total-STAT3 and P-Y705 in ST2-treated tumors was comparable to control-treated tumors, consistent with the persistent expression of STAT3 β and the maintenance of this phosphorylation site (Figure 5F, H). IHC for P-S727 (present only in STAT3 α) was negative for both ST2 and ST6 treated tumors, further confirming the efficacy of these treatments at the protein level (Figure 3G). Analysis of tumor sections stained for Hematoxylin and Eosin (H&E, Figure 3I), showed that the ST2-induced splicing switch is the only treatment associated with a significant effect on tumor morphology. Of particular interest is that while STAT3 knock-down was effective at the




Figure 5. Effect of STAT3 alternative splicing modulation *in vivo*. (A) Following subcutaneous injection of 10×10^6 MDA-MB-435s cells, tumors of $\sim 100 \text{ mm}^3$ were treated intratumorally with 0.12mg of *in vivo*-Morpholino (PBS, INV, ST2 and ST6) twice a week for 3 weeks (arrows) and tumor volumes were measured. (B) Representative image of mice in each treatment group at time of sacrifice, with H&E staining of tumor sections underneath. (C, D) RT-PCR analysis of STAT3 exon 23 and exon 6 levels (respectively) in three tumors for each treatment group. GAPDH was used as control. (E) Epitopes' location of STAT3 antibodies used for the IHC staining. (F, G and H) Representative images of tumor sections from the 4 different treatment groups following IHC using specific antibodies against P-Y705, P-S727 and total STAT3, respectively. (I) Representative images of H&E stained tumor sections from the 4 different treatment groups.

molecular level, it did not have any notable effects on tumor morphology and growth compared to controls (Figure 3I).

Expression of LEDGF, Cyclin C, STAT1b and PCAF and IL8 is also inhibited in MDA-MB-435s-derived tumors in mice upon STAT3b activation, like previously described for the MDA-MB-435s cell lines. To assess whether their suppressive role in STAT3b-induced cell death also applies to in vivo tumor growth and progression when overexpressed, we started set up an in vivo system using the stable cell lines described above.

In experiments carried out in the de Stanchina lab, new baselines for tumor growth were derived in 8-10 weeks old athymic female mice, which were subcutaneously inoculated with 10X10⁶ MDA-MB-435s cells expressing STAT1b and PCAF. In addition, MDA-MB-435s-derived CyclinC and LEDGF cell lines are being currently re-generated from novel individual clones, as the expression in the previous clones resulted unstable. Next, a set of experiments using MDA-MB-435s cells overexpressing PCAF, STAT1b and control MDA-MB-435s, divided in 3 treatment group each (mock, INV and ST2 for splicing re-direction, 5 mice per group) have been started, with Vivo-Morpholino administered intratumorally at a final concentration of 0.12mg/30ul, twice a week. Tumor-bearing mice are assessed for weight loss and tumor volume twice weekly. Tumor volumes were determined by caliper. Tumor samples were harvested, to be analyzed by immunohistochemistry and at the RNA and protein levels. Unfortunately there was an issue with tumor up-take, so the results of these experiments are not conclusive and will need to be repeated for statistical significance. However, our initial indications suggest that in the presence of overexpressed PCAF (and to a lesser extent STA1b) the treatment with the splice-switching ST2 vivo-morpholino compound leads to a reduction in tumor growth, although such reduction does not appear to be as effective as when PCAF is not over-expressed, in which case a full tumor regression is observed. This is important, because (if confirmed) it suggests that also in this xenograft in vivo system, PCAF plays a key role in mediating Stat3beta anti-tumoral activity.

As well as repeating and completing the experiment delineated above, we have also designed FSD-NMD morpholino compounds to knock-down endogenous PCAF expression, and to induce endogenous expression to activate STAT1b. These have now been synthesized to be tested for activity in cell lines [Cartegni lab], Active compounds will then be used by themselves and in combination to test their anti-tumoral activity, to show that the anti-tumorigenic activity of the ST2 compounds is mediated by PCAF and/or STAT1b [de Stanchina lab].

In parallel, we have designed and synthesized morpholino compounds specific to either the human (ST2h) or mouse STAT3 exon 23 sequence (ST2m), which induce activation of

STAT3b in either species but not in both. These have now been cross-tested in human and mouse cell lines to confirm that they can effectively and specifically activate STAT3beta in a species-specific way [Cartegni lab]. Similarly to previous experiments, the comparison in vivo using the MDA-Mb-435s model to compare targeting the tumor proper exclusively (ST2h) vs. targeting the tumor environment exclusively (ST2m) vs. targeting both (ST2) are ready to be undertaken in the de Stanchina lab.

Finally, next-generation compounds, based on alternative chemistry (2'MOE) and alternative delivery system (peptide-based) have been designed and synthesized and initial testing are undergoing in the Cartegni lab. Similarly, initial optimization procedures to establish a second, complementary model of aggressive breast cancer using MDA-MB-231 subpopulation LM2-4175[33] cells subcutaneously (as above), systemically (via injection into the left ventricle) or orthotopically into axillary mammary fat pads of 6-week old female athymic nude mice are underway in the de Stanchina lab. This cell line expresses luciferase, which allows for accurate quantification of tumor growth, and induces lung metastases, which will allow us to test for compound efficacy in metastatic conditions. For mammary-fat-pad tumor assays, 3 million cells resuspended in a 50:50 solution of PBS and Matrigel are directly injected into the mammary fat pad corresponding to gland #3. For cardiac injections, 1 million cells resuspended in 100 ul PBS are injected into the left ventricle of anesthetized mice. Tumor progression is visualized by weekly imaging. To do so, mice will be injected with D-luciferin (Xenogen) at 50 mg kg and Photonic emission captured with the In Vivo Imaging System (IVIS, Xenogen). Tumor bioluminescence is then quantified by integrating the photonic flux (photons per second) through a region encircling each tumor, as determined by the LIVING IMAGES software package (Xenogen).

Calibration experiments for imaging have been performed and usage of this model with the ST2 compound will begin in the next funding period.

KEY RESEARCH ACCOMPLISHMENTS

1. Generation of improved stable MDA-MB-435s cell lines overexpressing LEDGF and CyclinC
2. Effect on tumor growth of overexpression of PCAF or STAT1b
3. Effect of STAT3 alpha-beta induction on growth of tumors overexpressing PCAF or STAT1b
4. Design and testing of morpholino compounds targeted to PCAF (FSD-NMD) and STAT1b (splice-switching)
5. Design and testing of morpholino compounds specifically targeted to mouse or human STAT3 exon 23
6. Design and testing of 2'MOE compounds
7. Establishment and calibration of the MDA-MB-231 (LM2-4175) model system

REPORTABLE OUTCOMES

1. **Lee Spraggon and Luca Cartegni**; Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy, *Drug Discovery Today: Therapeutic Strategies* (2013) <http://dx.doi.org/10.1016/j.ddstr.2013.06.002>

CONCLUSIONS

STAT3 is an oncogene transcription factor whose constitutive activation in a large majority of tumors, including breast cancer, is thought to contribute to multiple aspects of the tumorigenesis process. Its main alternative splicing isoform, STAT3b, can act as a dominant negative factor that, when overexpressed in cancer cells, is able to inhibit cell growth in vitro and in vivo. In addition to its dominant negative functions, STAT3b is also in direct transcriptional control of some specific pathways, with antitumorigenic properties, which are independent of the full length STAT3 activities. This Sta3b-specific targets include PCAF, LEDGF, IL8, Cyclin C and STAT1b.

We have previously shown that the modulation of STAT3/STAT3b relative expression levels via splicing re-direction compounds, can lead to a potent anti-tumorigenic approach through the modulation of the above mentioned STAT3b specific set of target genes.

The first funding period of this project has been instrumental in the setup of numerous experimental systems, with the multiple targets described in the specific aims of the project. In particular, a lot of the early work in the Cartegni lab has been focused on the exploration of the specific role of the a few STAT3b targets (PCAF, LEDGF, IL8, STAT1b) with the determination of their causal involvement in anti-tumorigenic activities.

In addition, the design, synthesis and initial testing of new compounds to regulate the above mentioned targets and to develop next generation, more active STAT3 splicing redirection compounds, or compounds that interrogate the role of STAT3beta in the tumor proper or in the tumor environment has been carried out in the Cartegni lab.

At the same time the de Stanchina lab has proceeded in the establishment of multiple novel in vivo systems, including those aimed at assessing the role of the above mentioned STAT3b targets in vivo, those aimed at testing the role of Stat3beta in the tumor microenvironment and those directed at the establishment of a second, aggressive breast cancer system which incorporates a luciferase readout, This will also provide the possibility to assess the effectiveness of all the above compounds (first and second generation) by themselves or in combination with traditional chemotherapy in a metastatic model of breast cancer.

A major hurdle, which has been associated with the interruption of the research project at the end of the first funding period, has been the transfer of the laboratory of Dr. Cartegni's from Memorial Sloan-Kettering Cancer Center, New York, to the Susan Lehman Cullman

Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, New Jersey.

The transfer initiated at the end of September 2013 has taken significantly more time than expected and the new laboratory has become fully operative only in February 2014. In addition to the 4 months 'down-time', additional delays compared to the original timeline are expected because of the need to train and bring up to speed the new personnel that have been hired for the task.

Importantly, no DOD funds from this grant have been used, at MSK or at Rutgers, since the move has started in September 2013 in order to wait for the laboratory to become fully operative and the fund situation to be clarified. No changes occurred within the lab of Dr. de Stanchina (MSKCC), so nothing is expected to change regarding that part of the project, although experiments have been suspended for the delay period in her laboratory as well.

Lehman Cullman Laboratory for Cancer Research at Rutgers university is a prestigious institution that will fully provide all the needed equipment, support and expertise needed to carry out the project as anticipated.

The only significant difference anticipated is that we will be asking for a no-cost six months extension at the end of the final funding period to compensate the delay due to the move of Dr. Cartegni's lab.

REFERENCES

1. Levy DE, Darnell JE, Jr. (2002) Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol* 3: 651-662.
2. Darnell JE, Jr. (2002) Transcription factors as targets for cancer therapy. *Nat Rev Cancer* 2: 740-749.
3. Levy DE, Lee CK (2002) What does Stat3 do? *J Clin Invest* 109: 1143-1148.
4. Akira S (2000) Roles of STAT3 defined by tissue-specific gene targeting. *Oncogene* 19: 2607-2611.
5. Haura EB, Turkson J, Jove R (2005) Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. *Nat Clin Pract Oncol* 2: 315-324.
6. Wegrzyn J, Potla R, Chwae YJ, Sepuri NB, Zhang Q, et al. (2009) Function of mitochondrial Stat3 in cellular respiration. *Science* 323: 793-797.
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, et al. (1999) Stat3 as an oncogene. *Cell* 98: 295-303.
8. Jing N, Tweardy DJ (2005) Targeting Stat3 in cancer therapy. *Anticancer Drugs* 16: 601-607.
9. Yu H, Jove R (2004) The STATs of cancer--new molecular targets come of age. *Nat Rev Cancer* 4: 97-105.
10. Levy DE, Inghirami G (2006) STAT3: a multifaceted oncogene. *Proc Natl Acad Sci U S A* 103: 10151-10152.
11. Kortylewski M, Yu H (2008) Role of Stat3 in suppressing anti-tumor immunity. *Curr Opin Immunol* 20: 228-233.
12. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 9: 798-809.
13. Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, et al. (2008) Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. *Mol Cancer Ther* 7: 3169-3175.
14. Lo HW, Cao X, Zhu H, Ali-Osman F (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. *Clin Cancer Res* 14: 6042-6054.
15. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, et al. (1997) Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. *Cell Growth Differ* 8: 1267-1276.
16. Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP (1997) Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. *Cancer Res* 57: 978-987.
17. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, et al. (2005) New and old functions of STAT3: a pivotal target for individualized treatment of cancer. *Cell Cycle* 4: 1131-1133.
18. Niu G, Shain KH, Huang M, Ravi R, Bedi A, et al. (2001) Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. *Cancer Res* 61: 3276-3280.
19. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, et al. (2006) Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. *Clin Cancer Res* 12: 7140-7148.
20. Ling X, Arlinghaus RB (2005) Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. *Cancer Res* 65: 2532-2536.
21. Li GH, Wei H, Lv SQ, Ji H, Wang DL (2010) Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. *Int J Oncol* 37: 103-110.
22. Yang F, Brown C, Buettner R, Hedvat M, Starr R, et al. (2010) Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3. *Mol Cancer Ther*.
23. Yue P, Turkson J (2009) Targeting STAT3 in cancer: how successful are we? *Expert Opin Investig Drugs* 18: 45-56.

24. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, et al. (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. *Clin Cancer Res* 12: 20-28.
25. Zammarchi F, de Stanchina E, Bournazou E, Supakorndej T, Martires K, et al. (2011) Antitumorigenic potential of STAT3 alternative splicing modulation. *Proc Natl Acad Sci U S A* 108: 17779-17784.
26. Spraggon L, Cartegni L (2013) Antisense modulation of RNA processing as a therapeutic approach in cancer therapy. *Drug Discovery Today: Therapeutic Strategies*.
27. Cartegni L, Krainer AR (2003) Correction of disease-associated exon skipping by synthetic exon-specific activators. *Nat Struct Biol* 10: 120-125.
28. Llano M, Morrison J, Poeschla EM (2009) Virological and cellular roles of the transcriptional coactivator LEDGF/p75. *Curr Top Microbiol Immunol* 339: 125-146.
29. Crane DI, Maxwell MA, Paton BC (2005) PEX1 mutations in the Zellweger spectrum of the peroxisome biogenesis disorders. *Hum Mutat* 26: 167-175.
30. Ren S, Rollins BJ (2004) Cyclin C/cdk3 promotes Rb-dependent G0 exit. *Cell* 117: 239-251.
31. Nagy Z, Tora L (2007) Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. *Oncogene* 26: 5341-5357.
32. Baran-Marszak F, Feuillard J, Najjar I, Le Clorennec C, Bechet JM, et al. (2004) Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. *Blood* 104: 2475-2483.
33. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. *Nature* 459: 1005-1009.

APPENDICES	none
SUPPORTING DATA	none